sg001
mAbexperimental
Clinical trial activity
14 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
12
Phase 3
2
Phase 4
0
Earliest trial started Mar 28, 2019 (NCT03852823)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Ovarian Epithelial · Phase 2
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2/Phase 3
- Fallopian Tube Neoplasms · Phase 2
- Gallbladder Neoplasms · Phase 2
- Hamartoma · Phase 2
- Lymphoma · Phase 1
- Mesothelioma, Malignant · Phase 1
- Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 3
Mechanism of action
- 80S RibosomeINHIBITOR
80S Ribosome inhibitor
- 60S ribosomal protein L39 (RPL39) ↗
- 60S ribosomal protein L41 (RPL41) ↗
- 40S ribosomal protein S15 (RPS15) ↗
- 40S ribosomal protein S15a (RPS15A) ↗
- 40S ribosomal protein S16 (RPS16) ↗
- 40S ribosomal protein S17 (RPS17) ↗
- 40S ribosomal protein SA (RPSA) ↗
- 40S ribosomal protein S18 (RPS18) ↗
- 40S ribosomal protein S19 (RPS19) ↗
- 40S ribosomal protein S20 (RPS20) ↗
- 40S ribosomal protein S21 (RPS21) ↗
- 40S ribosomal protein S23 (RPS23) ↗
- 40S ribosomal protein S24 (RPS24) ↗
- 40S ribosomal protein S25 (RPS25) ↗
- 40S ribosomal protein S27 (RPS27) ↗
- 40S ribosomal protein S26 (RPS26) ↗
- Ubiquitin-40S ribosomal protein S27a (RPS27A) ↗
- 40S ribosomal protein S28 (RPS28) ↗
- 40S ribosomal protein S29 (RPS29) ↗
- 40S ribosomal protein S30 (RS30) ↗
- 60S ribosomal protein L21 (RPL21) ↗
- 60S ribosomal protein L22 (RPL22) ↗
- 60S ribosomal protein L23 (RPL23) ↗
- 60S ribosomal protein L23a (RPL23A) ↗
- 60S ribosomal protein L24 (RPL24) ↗
- 40S ribosomal protein S6 (RPS6) ↗
- 60S ribosomal protein L26 (RPL26) ↗
- 60S ribosomal protein L27 (RPL27) ↗
- 60S ribosomal protein L27a (RPL27A) ↗
- 60S ribosomal protein L28 (RPL28) ↗
- 60S ribosomal protein L29 (RPL29) ↗
- 60S ribosomal protein L30 (RPL30) ↗
- 60S ribosomal protein L31 (RPL31) ↗
- 60S ribosomal protein L32 (RPL32) ↗
- 60S ribosomal protein L34 (RPL34) ↗
- 60S ribosomal protein L35 (RPL35) ↗
- 60S ribosomal protein L35a (RPL35A) ↗
- 60S ribosomal protein L36 (RPL36) ↗
- 60S ribosomal protein L36a (RPL36A) ↗
- 60S ribosomal protein L37 (RPL37) ↗
- 40S ribosomal protein S10 (RPS10) ↗
- 40S ribosomal protein S11 (RPS11) ↗
- 40S ribosomal protein S12 (RPS12) ↗
- 40S ribosomal protein S13 (RPS13) ↗
- 40S ribosomal protein S14 (RPS14) ↗
- 60S ribosomal protein L37a (RPL37A) ↗
- 40S ribosomal protein S2 (RPS2) ↗
- 40S ribosomal protein S3 (RPS3) ↗
- 40S ribosomal protein S3a (RPS3A) ↗
- 40S ribosomal protein S4, X isoform (RPS4X) ↗
- 40S ribosomal protein S4, Y isoform 1 (RPS4Y1) ↗
- 40S ribosomal protein S5 (RPS5) ↗
- 40S ribosomal protein S7 (RPS7) ↗
- 40S ribosomal protein S8 (RPS8) ↗
- 40S ribosomal protein S9 (RPS9) ↗
- 60S ribosomal protein L3 (RPL3) ↗
- 60S ribosomal protein L4 (RPL4) ↗
- 60S ribosomal protein L5 (RPL5) ↗
- 60S ribosomal protein L6 (RPL6) ↗
- 60S ribosomal protein L7 (RPL7) ↗
- 60S ribosomal protein L7a (RPL7A) ↗
- 60S ribosomal protein L8 (RPL8) ↗
- 60S ribosomal protein L9 (RPL9; RPL9P7; RPL9P8; RPL9P9) ↗
- 60S ribosomal protein L10 (RPL10) ↗
- 60S ribosomal protein L10a (RPL10A) ↗
- 60S ribosomal protein L11 (RPL11) ↗
- 60S ribosomal protein L12 (RPL12) ↗
- 60S ribosomal protein L13 (RPL13) ↗
- 60S ribosomal protein L13a (RPL13A) ↗
- 60S ribosomal protein L14 (RPL14) ↗
- 60S ribosomal protein L15 (RPL15) ↗
- 60S ribosomal protein L17 (RPL17) ↗
- 60S ribosomal protein L18 (RPL18) ↗
- 60S ribosomal protein L18a (RPL18A) ↗
- 60S ribosomal protein L19 (RPL19) ↗
- 60S ribosomal protein L38 (RPL38) ↗
- 60S acidic ribosomal protein P0 (RPLP0) ↗
- 60S acidic ribosomal protein P1 (RPLP1) ↗
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07251062 | Phase 2/Phase 3 (Phase 3) | Dec 30, 2025 | Shijiazhuang Pharma Group (CSPC) |
| NCT06989671 | Phase 2 | Aug 30, 2025 | Shijiazhuang Pharma Group (CSPC) |
| NCT07183865 | Phase 2 | Mar 9, 2025 | Fudan University |
| NCT06682611 | Phase 1/Phase 2 (Phase 2) | Nov 13, 2024 | — |
| NCT06089330 | Phase 2 | Jan 31, 2024 | Shanghai JMT-Bio Inc. |
| NCT06132217 | Phase 1/Phase 2 (Phase 2) | Jan 30, 2024 | — |
| NCT06136988 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Shijiazhuang Pharma Group (CSPC) |
| NCT05715840 | Phase 3 | Jan 31, 2023 | Shijiazhuang Pharma Group (CSPC), Tsinghua University |
| NCT05508659 | Phase 1/Phase 2 (Phase 2) | Sep 20, 2022 | Shijiazhuang Pharma Group (CSPC) |
| NCT05068141 | Phase 2 | Oct 1, 2021 | Shijiazhuang Pharma Group (CSPC), Sun Yat-Sen University |
| NCT05009953 | Phase 2 | Sep 30, 2021 | Chinese Academy of Medical Sciences, Yiling Pharmaceutical Inc. |
| NCT04983550 | Phase 2 | Sep 30, 2021 | Shijiazhuang Pharma Group (CSPC) |
| NCT04886700 | Phase 2 | Jul 31, 2021 | Chinese Academy of Medical Sciences, Shijiazhuang Pharma Group (CSPC) |
| NCT03852823 | Phase 1 | Mar 28, 2019 | Shijiazhuang Pharma Group (CSPC) |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shijiazhuang Pharma Group (CSPC) | For profit | 9 | 9 | 3 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Shanghai JMT-Bio Inc. | For profit | 1 | 1 | 1 | 2024 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Tsinghua University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Yiling Pharmaceutical Inc. | For profit | 1 | 1 | 1 | 2021 |
7 organizations
Page 1 / 1